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Abstract: Despite significant progress made in the overall cure rate, the prognosis for relapsed 
and refractory malignancies in children remains extremely poor. Hence, there is an urgent need 
for studies that enable the timely selection of appropriate agents for Phase I clinical studies. 
The Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC) is 
systematically evaluating libraries of known and novel compounds for activity against subsets 
of high-risk pediatric malignancies with defined molecular aberrations for future clinical 
development. In this report, we describe the in-vitro activity of a diverse panel of approved 
oncology drugs against MLL-rearranged pediatric leukemia cell lines. Agents in the Approved 
Oncology Drug Set II (National Cancer Institute/National Institutes of Health Developmental 
  Therapeutics Program) were evaluated by in-vitro cytotoxicity assays in pediatric acute lym-
phoblastic leukemia and acute myeloid leukemia cell lines with MLL gene rearrangements. 
Validation studies were carried out with patient leukemia cells in culture. Comparative analysis 
for toxicity against nonmalignant cells was evaluated in normal bone marrow stromal cells and 
normal human lymphocytes. Results from this study show that 42 of the 89 agents tested have 
measurable cytotoxicity against leukemia cells, and among these, 12 were effective against all 
five MLL-rearranged cell lines (IC50 [half maximal inhibitory concentration] , 1 µM). These 
12 agents include cladribine, dactinomycin, daunorubicin, docetaxel, etoposide, gemcitabine, 
mitomycin C, mitoxantrone, teniposide, topotecan, triethylenemelamine, and vinblastine. We 
show that the Approved Oncology Drug Set II contains a number of agents with potent antileu-
kemic activity in the tested cell lines. As approved drugs, these agents have been used in clinical 
settings for many years for other malignancies, thus their toxicity profile, pharmacokinetics, 
and other properties are readily available. Further evaluation of their use in future clinical trials 
for pediatric leukemia with MLL abnormalities should be considered.
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Introduction
Survival rates for acute lymphoblastic leukemia (ALL) have increased dramatically 
over the last 20 years. Up to 80% of children diagnosed with ALL can be cured with the 
current treatment regimens.1 The improvement in cure rate is due to systematic clinical 
trials with risk stratification of patients during treatment, the institution of intrathecal 
therapy, the intensification of treatment with existing drugs, and the identification of OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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better and combinations of chemotherapeutics.2 However, 
the remaining 20% of pediatric patients with leukemia have 
very poor outcomes with current treatment strategies; these 
patients often have relapsed or refractory leukemias with 
distinct molecular abnormalities that categorize them as high-
risk.3 The identification of effective therapeutic strategies 
for these high-risk subgroups remains an important goal for 
improving survival rates in children with leukemia.
Rearrangement of chromosome band 11q23 at the MLL 
gene (mixed-lineage-leukemia) is common and associated 
with a particularly poor prognosis for all pediatric age 
groups presenting with ALL.4 The most aggressive forms 
of MLL-rearranged ALL involve balanced translocations 
at t(4;11), t(11;19), or t(9;11).4,5 MLL gene rearrangements 
occur in 80% of children with ALL diagnosed before 1 year 
of age.2,6,7 The t(4;11) or t(11;19) translocations are the most 
common 11q23 abnormality in infants.5 These patients 
are most often categorized as high- or very high-risk and 
often experience early treatment failure.5–8 The presence of 
any MLL-rearrangement is associated with a significantly 
poorer prognosis for infants compared with patients whose 
leukemias possess germ line MLL.5–7 This also holds true for 
children who are 1–9 years of age; the presence of t(4;11) 
or t(9;11) translocations is associated with a poor prognosis 
compared with other 11q23 abnormalities, such as deletion of 
11q23 or different translocations,5 or compared with patients 
with germ line MLL.4,6 MLL gene rearrangements also occur 
in up to 20% of acute myeloid leukemia (AML) cases and, 
in general, portend a poor outcome.9,10
Currently, intense strategies such as stem-cell transplan-
tation are needed to treat MLL-rearranged acute leukemias, 
and the outcome still remains poor. Hence, novel therapeutic 
approaches are urgently needed to improve the outcome in 
these patients.11 Cell lines derived from leukemia specimens 
have been instrumental in advancing current knowledge and 
treatment options in a number of hematological   malignancies. 
Drexler and colleagues have described the utility of cell 
lines as experimental models for the study of MLL gene 
  alterations.12 It has been hypothesized that such cell lines 
will help to understand the role of the MLL genetic aberration 
on the pathogenic process of the disease and will enable the 
effective identification of agents on a proximate model of the 
human disease.12 The Pediatric Oncology Experimental Ther-
apeutics Investigators’ Consortium (POETIC) has established   
a program to screen cell lines that represent functionally cru-
cial molecular alterations with relevance to currently difficult 
to cure pediatric malignancies for the purpose of designing 
future clinical trials. These studies are aimed to provide ini-
tial preclinical data to identify drugs with potential that can 
be further evaluated in mechanistic, drug combination and 
xenograft studies to facilitate timely development of Phase I 
studies. In this manuscript, we describe the evaluation of   
current and novel chemotherapeutic agents using drug panels 
provided by the National Cancer Institute/National Institutes 
of Health (NCI/NIH) Developmental Therapeutics Program 
(DTP). In comparison to currently used chemotherapeutic 
agents, this screen resulted in the identification of many 
active agents not typically used in the treatment of pediatric 
leukemia, providing important data for further studies.
Methods
Tissue culture and cell lines
All cell lines were maintained in OptiMEM I Reduced 
Serum Media (31985-070, Invitrogen, Carlsbad, CA), 
supplemented with 10% fetal calf serum and 100 units/mL 
each of penicillin and streptomycin. Cells were incubated 
at 37°C with 5% CO2 buffering. Characteristics of the cell 
lines are shown in Table 1.
reagents
The Approved Oncology Drug Set II was obtained from the 
NCI/NIH DTP Open Chemical Repository.13 All agents were 
solubilized in dimethylsulfoxide (DMSO) (D5879, Sigma 
Aldrich, Oakville, ON, Canada) at 10 mM stock concentra-
tion and stored at -20°C.
Drug screen
The Approved Oncology Drug Set II was screened using 
KOPN8, SEM, B1, MOLT-3, and TIB-202 cell lines at 10.00, 
1.00, 0.10, and 0.01 µM concentrations in duplicate wells of 
Table 1 characteristics of human leukemia cell lines
Cell line Diagnosis MLL rearrangement Age/gender of patient Reference
seM relapsed preB-ALL t(4;11)(q21;q23) 5 years/F greil et al43
B1 relapsed preB-ALL t(4;11)(q21;q23) 14 years/M cohen et al44
KOPn8 preB-ALL t(11;19)(q23;p13) 3 months/F Matsuo and Drexler45
MOLT-3 T-ALL t(4;11)(q21;q23) 19 years/M Minowada et al46
TiB-202 AML t(9;11)(p22;q23) 1 year/M Tsuchiya et al,47 Adati et al48
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; F, female; M, male; preB, precursor B.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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96-well plates (655180, Greiner Bio-One, Monroe, NC). 
Control wells contained an equivalent amount of DMSO. 
Cells were plated at 5 × 103 cells/well in the presence of 
drug treatment and incubated at 37°C with 5% CO2 buffer-
ing. After 96 hours, cell numbers were measured by direct 
cell counting with brightfield analysis using the Celigo™ 
cytometer14 (Cyntellect Inc, San Diego, CA). Validity of 
the single round of screening was confirmed by random 
selection of 11 drugs from the Approved Oncology Drug 
Set II. These were re-screened as above. The repeated 
samples closely confirmed the half maximal inhibitory 
concentration (IC50) values calculated from the first round 
of screening.
cell survival assays
A subset of drugs from the Approved Oncology Drug Set II 
was selected for follow-up analysis. Criteria for selection of 
these drugs included an IC50 , 1 µM in four cell lines and 
limited use in current pediatric leukemia treatment protocols. 
Methotrexate (MTX) and cytarabine (AraC) were also included 
for comparison. Cells were treated with the drugs as described 
above, except that triplicate wells were used with 1:10 serial 
dilutions ranging from 10 µM down to 1 × 10–10 µM. After 
96 hours, viable cell numbers were measured by direct cell 
counting using the Celigo cytometer. Additionally, cell num-
bers were measured at 24, 48, 72, and 96-hour time points using 
the Celigo cytometer. The survival percentage was calculated 
by comparing the number of viable cells in treated wells to 
control (DMSO)-treated wells.
normal human samples
Bone marrow stromal (BMS) cells were isolated as previ-
ously described15 and used to evaluate the drug effects on 
nonleukemic cells. Normal human lymphocytes (NHL) were 
isolated by Ficoll gradient from whole blood of a healthy 
volunteer. Cells were treated with the selected Approved 
Oncology Drug Set II as described above, except that dupli-
cate wells were used with 1:10 serial dilutions ranging from 
10 µM down to 1 × 10–6 µM. The characteristics of the NHL 
and BMS (small size and very flat, respectively) prevented 
the software for the Celigo cytometer from directly count-
ing these samples. Instead, 5 µL of alamarBlue® (DAL1100, 
Invitrogen) was added to each well after 96 hours. The cells 
were incubated an additional 24 hours and then measured 
at 570 nm and 620 nm using an Opsys MR™ plate reader 
(Dynex Technologies, Chantilly, VA). Viability data from 
the alamarBlue assay closely agrees with direct counting by 
Celigo (Supplemental Figure 1).
Patient samples
Leukemia cells were obtained from samples collected for new 
therapies for pediatric leukemia research (DC study) following 
local Institutional Review Board approval and parental con-
sent. Leukemia cells were collected from a 3-month-old male 
diagnosed with precursor B-ALL (patient 17577; t(11;19)
(q23;p13)), an 8-month-old male with precursor B-ALL 
(patient 87781; t(11;19)(q23;p13)), and a 5-year-old male with 
T-ALL (patient 41304). Details of the treatment and leuke-
mia cell isolation procedures for patient 17577 are described 
elsewhere.16 Isolation procedures for patients 87781 and 41304 
were the same as for patient 17577. Patient cells were treated 
with the selected drugs from the Approved Oncology Drug Set 
II as described for the BMS cells, except that after 96 hours, 
cells were counted using the Celigo cytometer.
calculations and software
All IC50 values were calculated using Microsoft Excel® 
for Mac 2008 (version 12.2.6) (Microsoft Corporation, 
Redmond, WA). Heat maps were generated using Mayday 
computer software (version 1.0).17
rationale for model leukemia cell lines
Five different cell lines, all harboring MLL-gene rearrange-
ments (Table 1) were tested. The validity of using these cell 
lines to represent patient samples is confirmed by previous 
literature where gene expression profiles of ALL cell lines 
were compared with ALL patient samples.18 ALL cell lines 
and patient samples with MLL gene rearrangements clustered 
closely together, demonstrating that cell lines display gene 
expression profiles comparable to patient samples.18 The 
distinguishing feature of cell lines compared with patient 
samples was higher levels of proliferation-related genes in 
the cell lines.18 In addition, other gene expression studies 
have shown that patient samples with MLL gene rearrange-
ments cluster together, further suggesting the similarities 
of leukemias of this subset.19–22 This similar separation of 
MLL-rearranged subsets was also seen in AML.23 Based 
upon these previous reports, we performed in-vitro drug 
screening on the ALL and AML cell lines using the Approved 
Oncology Drug Set II.
Results
in-vitro activity of microtubule- 
interfering drugs
All five leukemia cell lines were initially screened with 
the entire Approved Oncology Drug Set II, which includes 
most current United States Food and Drug Administration OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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  (FDA)-approved anticancer drugs. For clarity, we have 
categorized these drugs into the following groups: 
microtubule-interfering drugs, nucleic acid-targeting drugs, 
enzyme-inhibitory drugs, receptor- or immuno-modulatory 
drugs, and miscellaneous drugs.
Drugs that both stabilized and destabilized microtubules 
had high activity against most of the leukemia cell lines 
(Figure 1). Studies have shown that the preclinical activity 
of a drug is correlated to higher Phase II overall response 
rates of that drug.23 This means that the greater the potency 
of a drug (ie, cytotoxicity at low concentrations), the   stronger 
the predictive value for success in Phase II trials.24 High 
activity is defined as having an IC50 less than 1 µM, which 
indicates the clinical potential for the drug to effectively 
inhibit leukemia cell growth at low doses and with few side 
effects in patients. In TIB-202, KOPN8, SEM, and B1 cells, 
the IC50 values for all four microtubule-interfering drugs 
(docetaxel, paclitaxel, vinblastine, and vincristine) were less 
than 0.1 µM (Figure 1A and Supplemental Table 1). In the 
T-ALL cell line MOLT-3, there was greater variation in the 
activity of these microtubule-interfering drugs: paclitaxel and 
vincristine had no effect (IC50 = 10 µM), whereas docetaxel 
(IC50 , 0.01 µM) and vinblastine (IC50 = 0.851 µM) were 
more cytotoxic (Supplemental Table 1). The activity of each 
drug was compared with MTX or AraC, which are commonly 
used as therapeutics for pediatric leukemia, by calculating 
the ratio of the IC50 of MTX or AraC to the IC50 of each 
drug, within one cell line. The ratios were plotted as a heat 
map, wherein green indicates higher activity   compared with 
MTX or AraC, and red indicates lower activity. Figure 1B 
illustrates the variable sensitivity of MOLT-3 to different 
microtubule-interfering drugs, and highlights the overall 
potency of these drugs in the leukemia cells tested. In general, 
the microtubule-interfering drugs had higher activity than 
MTX and AraC, although in TIB-202 cells, these drugs were 
not better than MTX.
in-vitro activity of nucleic  
acid targeting drugs
The leukemia cell lines were treated with nucleic acid 
targeting drugs that were further categorized as deoxyribo-
nucleic acid (DNA) damaging agents, DNA intercalating 
agents or nucleic acid synthesis inhibitors (Figure 2 and 
Supplemental Table 1). None of the DNA damaging agents 
was particularly active in more than one cell line, as seen 
by the dominant red coloring of the heat maps (Figure 2B). 
Mitomycin C, bleomycin, and triethylenemelamine showed 
moderate activity in some cell lines. Mitomycin C had an 
IC50 value less than 0.5 µM in all cell lines (Figure 2A and 
Supplemental Table 1). In contrast, all of the DNA interca-
lating agents (mitoxantrone, daunorubicin, doxorubicin, and 
dactinomycin) had high activity for inhibiting the growth of 
leukemia cell lines and were, in general, more active than 
MTX and AraC (Figure 2D); the IC50 for the majority of 
these agents was ,0.01 µM (Figure 2C and Supplemental 
Table 1). Drugs that inhibit nucleic acid synthesis had a wide 
range of activity against the leukemia cell lines tested. Most 
of these drugs had little activity, with IC50 values above the 
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Figure 1 ic50 and relative effectiveness of microtubule-interfering drugs. (A) The ic50 (µmol/L) from five leukemia cell lines are shown in a box-whisker plot. For each drug 
treatment, the vertical lines in each box represent the 25th, 50th, and 75th percentiles, and the horizontal lines represent the minimum and maximum values. ic50 values 
above or below the tested concentration ranges were rounded to the highest or lowest concentration tested, respectively. (B) Heat map of drug effectiveness compared 
with MTX or Arac. Values are a ratio of the ic50 of MTX or Arac to the ic50 of each drug. green, black, and red represent superior, equivalent, and inferior activity, 
respectively, to MTX or Arac. 
Abbreviations: Arac, cytarabine; ic50, half maximal inhibitory concentration; MTX, methotrexate.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Figure 2 ic50 and relative effectiveness of nucleic-acid targeting drugs. (A and B) DnA damaging agents. (C and D) DnA intercalating agents. (E and F) nucleic acid synthesis 
inhibitors. (A, C and E) The ic50 (µmol/L) from five leukemia cell lines are shown in a box-whisker plot. (B, D and F) Heat map of drug effectiveness compared with MTX 
or Arac. Values are a ratio of the ic50 of MTX or Arac to the ic50 of each drug. green, black, and red represent superior, equivalent, and inferior activity, respectively, to 
MTX or Arac. 
Abbreviations: Arac, cytarabine; DnA, deoxyribonucleic acid; ic50, half maximal inhibitory concentration; MTX, methotrexate.
tested concentration range (IC50 . 10 µM) (Figure 2E). The 
exceptions were clofarabine (IC50 , 0.1 µM for four of five 
cell lines), fludarabine (IC50 , 1 µM for four of five cell 
lines), pemetrexed (IC50 , 1 µM for four of five cell lines), 
and gemcitabine (IC50 , 0.05 µM). Additionally, clofarabine 
and gemcitabine were more active than MTX and AraC in 
the respective cell lines (Figure 2F).
in-vitro activity of enzyme-inhibitory 
drugs
A variety of enzyme-inhibitory drugs from the Approved 
Oncology Drug Set II were used to treat the leukemia cell 
lines. These drugs were further categorized based on their 
enzymatic targets: aromatase, DNA methyltransferase, his-
tone deacetylase, mammalian target of rapamycin (mTOR), OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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proteasome, topoisomerases, or tyrosine kinases (Figure 3 
and Supplemental Table 1). Aromatase inhibitors had little 
effect on the leukemia cell lines. Not only were the IC50 val-
ues around 10 µM (Figure 3A), they were less cytotoxic than 
MTX and AraC (Figure 3B). The DNA methyltransferase 
inhibitor azacitidine and the histone deacetylase inhibitor vor-
inostat had weak activity in most of the cell lines (Figure 3C). 
  However, vorinostat had slightly better activity compared 
with AraC in KOPN8 and both had superior activity compared 
with MTX in MOLT-3 (Figure 3D). In contrast, the mTOR 
inhibitors (everolimus, rapamycin), proteasome inhibitor 
(bortezomib), and topoisomerase inhibitors (topotecan, 
etoposide, teniposide) were more potent at inhibiting the 
leukemia cell lines (Figure 3C). Irinotecan was the exception, 
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Figure 3 ic50 and relative effectiveness of enzyme inhibitory drugs. (A and B) Aromatase inhibitors. (C and D) DnA methyltransferase, histone deacetylase, mTOr, 
proteasome, and topoisomase inhibitors. (E and F) Tyrosine kinase inhibitors. (A, C and E) The ic50 (µmol/L) from five leukemia cell lines are shown in a box-whisker plot.   
(B, D and F) Heat map of drug effectiveness compared with MTX or Arac. Values are a ratio of the ic50 of MTX or Arac to the ic50 of each drug. green, black, and red 
represent superior, equivalent, and inferior activity, respectively, to MTX or Arac. 
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which demonstrated lower activity compared with MTX or 
AraC (Figure 3D). Everolimus, rapamycin, and bortezomib 
showed greater variation in IC50 between cell lines (Figure 3C); 
however, most of the drugs in these categories were more 
active than MTX and AraC (Figure 3D). The tyrosine kinase 
inhibitors appeared to have more cell-specific effects, rather 
than global effects like some other chemotherapeutic agents 
(Figure 3E and F). For example, dasatinib, imatinib, and 
nilotinib showed large variation in the IC50 values between the 
cell lines   (Figure 3E). Overall, this category of drugs was less 
active than MTX and AraC, with some exceptions including 
dasatinib (Figure 3F). Lapatinib, sorafenib, and sunitinib had 
limited potency and were less cytotoxic compared with MTX 
and AraC (Figure 3E and F).
in-vitro activity of receptor-  
or immuno-modulatory drugs
Drugs that modulate receptors (epidermal growth factor 
receptor, estrogen receptor) or the immune response were 
tested in all five leukemia cell lines (Figure 4A and B). 
These drugs had little effect on leukemia cell lines, with 
IC50 values ∼10 µM (Figure 4A and Supplemental Table 1). 
All of these drugs had less activity compared with MTX and 
AraC, with the exception of MOLT-3 cells, in which these 
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Figure 4 ic50 and relative effectiveness of receptor-modulatory, immuno-modulatory and miscellaneous drugs. (A and B) receptor- and immuno-modulatory drugs. (C and 
D) Miscellaneous drugs. (A and C) The ic50 (µmol/L) from five leukemia cell lines are shown in a box-whisker plot. (B and D) Heat map of drug effectiveness compared with 
MTX or Arac. Values are a ratio of the ic50 of MTX or Arac to the ic50 of each drug. green, black, and red represent superior, equivalent, and inferior activity, respectively, 
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drugs   performed equivalently, and erlotinib, which was more 
active in MOLT-3 cells only (Figure 4B).
in-vitro activity of miscellaneous drugs
A number of drugs from the Approved Oncology Drug Set 
II that are photo-activated, protective adjuvants or have 
miscellaneous function were tested in the leukemia cell lines 
(Figure 4C and D). None of the photo-activated agents or 
the protective adjuvant drugs had any effect on leukemia cell 
survival rates (IC50 = 10 µM) (Figure 4C and Supplemental 
Table 1). Only two drugs in the miscellaneous category, 
arsenic trioxide and acrichine, had any activity for inhibit-
ing leukemia cell growth. These drugs were cytotoxic only 
in KOPN8 cells, with IC50 values equal to 0.169 µM and 
0.722 µM, respectively (Figure 4C). However, none of these 
drugs showed higher cytotoxicity compared with MTX or 
AraC in more than one cell line (Figure 4D).
in-vitro activity of selected candidate 
drugs in leukemia cell lines
To investigate the possibility that drugs from the Approved 
Oncology Drug Set II could be translated into therapies 
for MLL-rearranged leukemias, we focused on a subset of 
drugs from the Approved Oncology Drug Set II for in-depth 
study. These drugs were included in the initial screen of the 
Approved Oncology Drug Set II, and were selected due to 
early indications of potency and diversity of mechanism 
of action. Additionally, we included in the analyses two 
drugs commonly used in pediatric oncology (MTX and 
AraC) for comparison with the selected drugs. The selected 
drugs were cladribine (nucleic acid synthesis inhibitor), 
decitabine (DNA methyltransferase inhibitor), ixabepilone 
(microtubule stabilizer), plicamycin (DNA intercalating 
agent), valrubicin (DNA intercalating agent and PKC inhibi-
tor), and vinorelbine (microtubule destabilizer). The mean 
IC50 (± standard error) for each drug in SEM, B1, KOPN8, 
MOLT-3, and TIB-202 cell lines were calculated from two 
to four experiments with two or three replicate wells per 
experiment (Table 2).
All of the selected candidate drugs showed significant 
cytotoxic activity against the leukemia cells lines, although 
several were less active in MOLT-3 cells than the other 
four cell lines (Table 2). As was seen for microtubule-
interfering drugs (Figure 1), both vinorelbine (Figure 5A) 
and ixabepilone (Figure 5C) were effective at inhibiting 
the growth of the leukemia cell lines at low doses. The 
IC50 values were less than 0.425 µM for all the cell lines 
except MOLT-3, which was resistant to both of these drugs 
(IC50 . 10 µM) (Table 2). The nucleic acid-related drugs 
cladribine (Figure 6A), plicamycin (Figure 6C), valrubicin 
(Figure 6E), and AraC (Figure 6G) all showed cytotoxicity 
against leukemia cells. All cell lines tested were sensitive to 
cladribine, including MOLT-3; however, TIB-202 cells were 
not sensitive to AraC, and MOLT-3 cells were not sensitive to 
Table 2 Mean ic50 values after incubation with selected drugs from the Approved Oncology Drug set ii
Drug name 
(NSC  
numbera)
IC50 (μmol/L) 
Meanb ± SE
Cell line
SEM B1 KOPN8 MOLT-3 TIB-202
cladribine  
(105014)
8.85 × 10–2 ± 3.31 × 10–3 3.45 × 10–1 ± 3.53 × 10–1 5.44 × 10–2 ± 1.21 × 10–2 7.95 × 10–1 ± 1.78 × 10–1 2.63 × 10–1 ± 2.47 × 10–1
cytarabine  
(63878)
2.92 × 10–1 ± 3.07 × 10–1 1.57 × 100 ± 1.98 × 100 5.78 × 10–1 ± 4.93 × 10–1 2.96 × 10–1 ± 2.59 × 10–1 3.49 × 100 ± 4.08 × 100
Decitabine  
(127716)
.1.00 × 101 2.33 × 10–1 ± 3.08 × 10–1 8.42 × 10–3 ± 9.51 × 10–4 3.19 × 10–1 ± 2.38 × 10–1 5.13 × 10–1 ± 3.05 × 10–1
ixabepilone  
(747973)
6.12 × 10–3 ± 1.09 × 10–3 4.41 × 10–2 ± 3.05 × 10–2 6.19 × 10–3 ± 4.05 × 10–3 .1.00 × 101 6.64 × 10–2 ± 3.37 × 10–2
Methotrexate  
(740)
6.17 × 10–2 ± 2.90 × 10–2 6.11 × 10–2 ± 3.55 × 10–2 2.54 × 10–2 ± 1.80 × 10–2 .1.00 × 101 1.41 × 10–1 ± 4.18 × 10–2
Plicamycin  
(24559)
2.24 × 10–2 ± 2.19 × 10–2 5.52 × 10–2 ± 2.48 × 10–2 1.45 × 10–2 ± 1.40 × 10–2 7.79 × 100 ± 3.13 × 100 4.47 × 10–2 ± 4.00 × 10–2
Valrubicin  
(246131)
4.13 × 10–2 ± 2.84 × 10–2 1.90 × 10–1 ± 1.63 × 10–1 6.95 × 10–2 ± 2.77 × 10–2 3.54 × 100 ± 4.09 × 100 2.95 × 10–1 ± 2.58 × 10–1
Vinorelbine  
(608210)
5.40 × 10–2 ± 2.62 × 10–2 2.70 × 10–1 ± 2.84 × 10–1 1.95 × 10–2 ± 8.20 × 10–3 .1.00 × 101 4.25 × 10–1 ± 1.89 × 10–1
Notes: aCompound identification number in the National Cancer Institute/National Institutes of Health Developmental Therapeutics Program database; bThe mean ic50 was 
calculated as the average of two–four replicates.
Abbreviations: ic50, half maximal inhibitory concentration; se, standard error.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Figure 5 Dose response and growth curves of selected microtubule-interfering drugs. Leukemia cell lines were incubated with vinorelbine (A and B) or ixabepilone 
(C and D). (A and C) cells were incubated with varying concentrations of drugs and assessed after 96 hours for survival compared with DMsO-treated cells. (B and D) 
cells were incubated with 1 µM of drug and assessed every 24 hours for cell survival compared with DMsO-treated cells. 
Notes: Data points and error bars are means and standard errors, respectively, of triplicate wells. A and c are representative of three separate experiments. 
Abbreviation: DMsO, dimethylsulfoxide.
plicamycin and   valrubicin (Table 2). Decitabine (Figure 7C) 
exhibited the greatest variation in activity across the cell 
lines: KOPN8 cells were the most sensitive (0.00842 µM), 
followed by B1 cells (0.233 µM), MOLT-3 cells (0.319 µM), 
and TIB-202 cells (0.513 µM). However, SEM cells appeared 
to be refractory to this drug (IC50 . 10 µM) (Table 2).
We compared the IC50 of each selected drug to MTX and 
AraC (Figure 8). All of the drugs showed superior activity 
compared with AraC in all cell lines except MOLT-3 cells. 
Plicamycin and ixabepilone showed the greatest degree of 
cytotoxicity compared with MTX in four out of five cell 
lines (ie, IC50 values were lower than or equivalent to the IC50 
of MTX). Vinorelbine was more active than MTX in three 
of the cell lines, and decitabine and valrubicin were more 
active than both MTX in two of the cell lines (Figure 8). 
Cladribine was less active than MTX in all but one cell line 
(MOLT-3). All of the selected drugs were less potent than 
MTX in TIB-202 cells, which showed good sensitivity to 
MTX alone (Figure 8 and Table 2).
Leukemia cell growth rates in the 
presence of selected candidate drugs
To further characterize the impact of the selected candi-
date drugs on leukemia cells, we monitored leukemia cell 
growth over time in the presence of the drugs. As suggested 
by the IC50 values of the microtubule-interfering drugs, 
vinorelbine (Figure 5B) and ixabepilone (Figure 5D) dra-
matically inhibited cell growth compared with control-treated 
cells. After 24 hours exposure to vinorelbine, KOPN8 and 
TIB-202 cells had half the viable cell numbers (52.3% and 
56.3%, respectively) compared with control (Figure 5B). 
By 96 hours, these values dropped to 10.4% and 12.5% of 
control, respectively. MOLT-3 cells had a slower decrease in 
cell numbers, which reached as low as 20.9% by 90 hours. 
Ixabepilone decreased cell numbers down to 10.8%–23.5% of 
control numbers after 90 hours (Figure 5D). Similar trends in 
cell growth were seen for cladribine (Figure 6B), plicamycin 
(Figure 6D), valrubicin (Figure 6F), AraC (Figure 6H), MTX 
(Figure 7B), and decitabine (Figure 7D).OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Figure 6 Dose response and growth curves of selected nucleic acid-related drugs. Leukemia cell lines were incubated with cladribine (A and B), plicamycin (C and D), valrubicin 
(E and F), or Arac (G and H). (A, C, E and G) cells were incubated with varying concentrations of drugs and assessed after 96 hours for survival compared with control DMsO-
treated cells. (B, D, F and H) cells were incubated with 1 µM of drug and assessed every 24 hours for cell survival compared with control DMsO-treated cells. 
Notes: Data points and error bars are means and standard errors, respectively, of triplicate wells. A, c, e, and g are representative of three separate experiments.
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Figure 7 Dose response and growth curves of selected enzyme-inhibitory drugs. Leukemia cell lines were incubated with MTX (A and B) or decitabine (C and D). (A and 
C) cells were incubated with varying concentrations of drugs and assessed after 96 hours for survival compared with control DMsO-treated cells. (B and D) cells were 
incubated with 1 µM of drug and assessed every 24 hours for cell survival compared with control DMsO-treated cells. 
Notes: Data points and error bars are means and standard errors, respectively, of triplicate wells. A and c are representative of three separate experiments. 
Abbreviations: DMsO, dimethylsulfoxide; MTX, methotrexate.
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Figure 8 relative effectiveness of selected drugs from the Approved Oncology 
Drug set ii on leukemia cell lines. Heat map of drug effectiveness compared with 
MTX or Arac. Values are a ratio of the ic50 of MTX or Arac to the ic50 of each 
drug. green, black, and red represent superior, equivalent, and inferior activity, 
respectively, to MTX or Arac. 
Abbreviations:  Arac,  cytarabine;  ic50,  half  maximal  inhibitory  concentration; 
MTX, methotrexate.
in-vitro activity of selected candidate 
drugs in patient cells
To determine off-target toxicity effects and the ability of the 
selected drugs to kill patient leukemia cells, the candidate drugs 
were also tested on normal bone marrow stromal (BMS) cells, 
NHL and leukemia cells from infants with MLL-rearranged 
ALL (Table 3). None of the tested drugs had any toxicity 
effects on NHL or BMS cells and were equivalent in potency 
as MTX and AraC (Figure 9). Patient 17577 was quite sensi-
tive to a number of the drugs in the selected panel (Figure 10). 
Cladribine, ixabepilone, plicamycin, valrubicin, and vinorelbine 
all had IC50 values under 1 µM (Table 3 and Figure 10), and were 
more potent than both MTX and AraC (Figure 9). Ixabepilone 
was particularly potent against cells from patient 17577, as cell 
survival dropped to only 32.9% of control-treated cells after 
48 hours (Figure 10B). Plicamycin, cladribine, and valrubicin 
demonstrated similar decreases in cell survival (39.2%, 47.2%, 
and 46.8%, respectively) after 48 hours (Figure 10D). In con-
trast, patients 87781 and 41304 were less sensitive to all of the OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Table 3 ic50 values after incubation with selected drugs from the Approved Oncology Drug set ii
Drug name IC50 (μmol/L)
BMSb Normal lymphocyte Patient 17577 Patient 87781 Patient 41304
cladribine (105014)a .1.00 × 101 .1.00 × 101 2.81 × 10–1 7.83 × 101 .1.00 × 101
Arac (63878) .1.00 × 101 .1.00 × 101 .1.00 × 101 5.30 × 101 9.26 × 101
Decitabine (127716) .1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101 4.56 × 101
ixabepilone (747973) .1.00 × 101 .1.00 × 101 4.64 × 10–6 .1.00 × 101 .1.00 × 101
MTX (740) .1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101 4.20 × 101
Plicamycin (24559) .1.00 × 101 .1.00 × 101 2.94 × 10–2 7.44 × 101 .1.00 × 101
Valrubicin (246131) .1.00 × 101 .1.00 × 101 3.71 × 10-1 4.85 × 101 .1.00 × 101
Vinorelbine (608210) .1.00 × 101 .1.00 × 101 3.81 × 10–3 .1.00 × 101 .1.00 × 101
Notes: aCompound identification number in the National Cancer Institute/National Institutes of Health Developmental Therapeutics Program database; brepresentative of 
two experiments.
Abbreviations: Arac, cytarabine; BMs, bone marrow stroma; ic50, half maximal inhibitory concentration; MTX, methotrexate.
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Figure 9 relative effectiveness of selected drugs from the Approved Oncology 
Drug set ii on normal and patient samples. Heat map of drug effectiveness compared 
with MTX or Arac. Values are a ratio of the ic50 of MTX or Arac to the ic50 
of each drug. green, black, and red represent superior, equivalent, and inferior 
activity, respectively, to MTX or Arac. 17577, 87781, and 41304 represent the 
patient samples. 
Abbreviations: Arac, cytarabine; BMs, bone marrow stroma; ic50, half maximal 
inhibitory concentration; MTX, methotrexate; nHL, normal human lymphocytes.
drugs, although some of the drugs did show better performance 
compared with MTX and AraC (Figure 9).
Discussion
These data suggest that a number of FDA-approved che-
motherapeutic agents have considerable activity against 
MLL-  rearranged ALL and AML cell lines and some patient 
samples. This paper forms part of key pre-clinical ground-
work for analysis of these agents as therapy for MLL-
  rearranged leukemia. We suggest that the data found herein 
form a basis for considering new treatment options for 
patients with MLL-rearranged leukemia following therapy 
with standard regimens.
We have identified a number of categories of drugs, as 
well as specific drugs, that are cytotoxic to MLL-rearranged 
cell lines. These include microtubule-interfering drugs, DNA 
intercalating agents, topoisomerase poisons, mTOR inhibi-
tors, and proteasome inhibitors. In addition to these catego-
ries of drugs, some specific agents, such as mitomycin C, 
gemcitabine, clofarabine, and dasatinib, showed better effi-
cacy than MTX and AraC. Overall, 42 out of the 89 agents 
tested were potent in at least one leukemia cell line. A total 
of 12 and 15 of these were potent in five or four cell lines, 
respectively, with an IC50 less than 1 µM. The twelve agents 
that were potent in all five cell lines include cladribine, 
docetaxel, vinblastine, mitomycin C, triethylenemelamine, 
mitoxantrone, daunorubicin, dactinomycin, gemcitabine, 
topotecan, etoposide, and teniposide. Some of the drugs, 
such as cladribine, ixabepilone, valrubicin, plicamycin, and 
vinorelbine, also performed well in the MLL-rearranged 
patient sample. Overall, this suggests there are a number 
of agents within the Approved Oncology Drug Set II that 
could be further evaluated for future clinical trials for MLL-
rearranged pediatric leukemia.
The most active drugs against the patient sample in this 
study were cladribine, ixabepilone, valrubicin, plicamycin, 
and vinorelbine. Cladribine has historically been used for 
treatment of hairy cell leukemia.25 However, it has also been 
used to treat several refractory hematological malignan-
cies, including AML.26,27 Complete and partial remission 
(CR and PR) rates were 27% and 32%, respectively, in 
pediatric AML patients pretreated with cladribine prior to 
induction therapy.27 Combination therapy of cladribine with 
AraC in adult AML patients who had relapsed or failed to 
respond to initial therapy enhanced the effective dose of 
AraC in the blood by 40% in seven out of nine patients.28 
However, cladribine should be used cautiously in patients OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 10 Dose response and growth curves of selected drugs with patient 17577 leukemia cells. cells isolated from patient 17577 were incubated with the indicated drugs. 
(A and C) cells were incubated with varying concentrations of drugs and assessed after 96 hours for survival compared with control DMsO-treated cells. (B and D) cells 
were incubated with 1 µM of drug and assessed every 24 hours for cell survival compared with control DMsO-treated cells. 
Note: Data points and error bars are means and standard errors, respectively, of triplicate wells. 
Abbreviations: Arac, cytarabin; DMsO, dimethylsulfoxide; MTX, methotrexate.
with renal dysfunction, as demonstrated by a case study of 
a pediatric AML patient treated with cladribine for 5 days.29 
These previous studies, along with the data in this paper, 
suggest some potential for cladribine during treatment 
of MLL-rearranged pediatric leukemia, as has been used 
anecdotally for a number of years, often when combined 
with etoposide.
The microtubule-interfering drugs produced promising 
results in this study. Vinorelbine, in combination with topote-
can, thiotepa, dexamethasone, and gemcitabine, has been used 
to treat patients with relapsed or refractory acute leukemia.30 
In one study, 36% of pediatric patients achieved CR and 11% 
achieved PR on this regimen.30 In another study, 37% of adult 
patients with refractory ALL achieved CR with a similar 
regimen.31 Ixabepilone is a new generation microtubule sta-
bilizer that has mainly been used for metastatic breast cancer 
therapy in patients with few treatment options.32 It has also 
been used in a Phase II trial of patients with a variety of treat-
ment-refractory sarcomas, malignant peripheral nerve sheath 
tumors, neuroblastoma, and Wilms tumors.33  Considering the 
potency of the microtubule-  interfering agents in this study 
and others,34 and the prominent use of vincristine in current 
leukemia treatment protocols, vinorelbine and ixabepilone 
are reasonable candidates for further consideration in MLL-
rearranged leukemias.
Valrubicin is a derivative of doxorubicin, an anthracyline 
antibiotic with DNA intercalation abilities. Valrubicin has 
only been used for treatment of bladder cancer35 and topi-
cal application of developing skin tumors.36 Although, not 
previously used in leukemia patients, the effectiveness of 
valrubicin in cell lines and the patient sample suggest it for 
further analysis as a new therapeutic for MLL-rearranged 
leukemia.
Some of the agents tested in these experiments have been 
used for leukemia or lymphoma treatment already, although 
they are not part of typical frontline treatment regimens. For 
example, decitabine has gained increasing attention in leu-
kemia and myelodysplastic syndrome settings.37,38 In Phase 
II studies of decitabine in combination with clofarabine and 
low-dose AraC, 59% of elderly patients with AML achieved OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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CR with manageable toxicity profiles.39 In adult patients 
with refractory AML, CR was achieved in 34% of patients 
who received decitabine therapy.40 POETIC is currently 
conducting a Phase I study of decitabine in combination 
with AraC, daunorubicin, and etoposide chemotherapy for 
newly diagnosed patients with AML. Plicamycin has also 
been used, in combination with interferon-α or hydroxyurea, 
to treat patients with chronic myeloid leukemia (CML) and 
myeloid blast crisis.41 This treatment regimen has had limited 
success in CML or AML therapy. Three of thirteen patients 
with CML had PR or CR, while two became stabilized on 
treatment.41 The median survival of these patients increased 
to 24 months from previously reported 6-month median 
survival.41 A Phase II study of plicamycin and hydroxurea in 
patients with high-risk, relapsed, or refractory AML resulted 
in no patients with CR or PR, and considerable toxicity.42 
These data suggest some caution against selecting plicamycin 
for clinical trial evaluation in pediatric patients with MLL-
rearranged leukemia.
In this report, we have attempted to identify agents that 
show effective in-vitro cytotoxicty against malignant cells 
and cell lines derived from patients with refractory leuke-
mia. However, the spectrum of effective agents includes 
drugs that have acceptable toxicities, as well as those that 
carry the potential to induce molecular abnormalities with 
increased risk of secondary malignancies in the future. In 
deciding future clinical application of any selected agent, 
the benefit of inducing remission in a highly refractory 
malignancy should be carefully considered against the risk 
of such possibilities. Similarly, we have based their activity 
profiles largely on IC50 values. Although lower IC50 values 
are generally considered to suggest effectiveness against 
neoplastic cells, it does not necessarily mean it would be 
the most applicable clinically because of untested toxicity in 
the patient. Utilization of the information presented in this 
paper should take into consideration, particularly in heav-
ily pretreated children, the potential adverse effects such 
as neurotoxicity, hepatotoxicity, and nephrotoxicity. Taken 
together, the results from this study highlight potential alter-
native therapeutic options for MLL-rearranged leukemias. 
The data presented herein demonstrate the need for further 
characterization of these drugs, either as single agents or in 
effective combination with novel targeted agents, for possible 
future clinical trials.
Acknowledgments
This work was supported by grants from the Kids Cancer 
Care Foundation of Alberta and the Alberta Children’s 
Hospital Foundation. RJA was funded in part through an 
endowed King Fahd Chair.
Disclosure
The authors have no conflicts of interest to declare.
References
  1.  Pui C-H, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 
1998;339:605–615.
  2.  Pieters R, Carroll WL. Biology and treatment of acute lymphoblastic 
leukemia. Hematol Oncol Clin North Am. 2010;24:1–18.
  3.  Biondi A, Cimino G, Pieters R, Pui C-H. Biological and therapeutic 
aspects of infant leukemia. Blood. 2000;96:24–33.
  4.  Behm FG, Raimondi SC, Frestedt, JL, et al. Rearrangement of the 
MLL gene confers a poor prognosis in childhood acute lymphoblastic 
leukemia, regardless of presenting age. Blood. 1996;87:2870–2877.
  5.  Pui C-H, Gaynon PS, Boyett JM, et al. Outcome of treatment in child-
hood acute lymphoblastic leukaemia with rearrangements of the 11q23 
chromosomal region. Lancet. 2002;359:1909–1915.
  6.  Chen CS, Sorensen PH, Reaman GH, et al. Molecular rearrangements 
on chromosome 11q23 predominate in infant acute lymphoblastic 
leukemia and are associated with specific biologic variables and poor 
outcomes. Blood. 1993;81:2386–2393.
  7.  Rubnitz JE, Link MP, Shuster JJ, et al. Frequency and prognostic signifi-
cance of HRX rearrangements in infant acute lymphoblastic leukemia: 
a Pediatric Oncology Group study. Blood. 1994;84:570–573.
  8.  Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic 
factors of acute lymphoblastic leukemia in infants: report on CCG 1953 
from the Children’s Oncology Group. Blood. 2006;108:441–451.
  9.  Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Hematol 
Oncol Clin North Am. 2010;24:35–63.
  10.  Martens JHA, Stunnenberg HG. The molecular signature of 
oncofusion proteins in acute myeloid leukemia. FEBS Lett. 2010; 
584:2662–2669.
  11.  Tamai H, Inokuchi K. 11q23/MLL acute leukemia: update of clinical 
aspects. J Clin Exp. 2010;50:91–98.
  12.  Drexler HG, Quentmeier H, MacLeod RA. Malignant hematopoietic cell 
lines: in vitro models for the study if MLL gene alterations. Leukemia. 
2004;18:227–232.
  13.  Development Therapeutics Program [homepage on the Internet]. NCI/
NIH. Available from: http://dtp.cancer.gov. Accessed July 23, 2011.
  14.  Nabzdyk CS, Chun M, Pradhan L, LoGerfo FW. High throughput 
RNAi assay optimization using adherent cell cytometry. J Transl Med. 
2011;9:48–56.
  15.  Narendran A, Ganjavi H, Morson N, et al. Mutant p53 in bone marrow 
stromal cells increases VEGF expression and supports leukemia cell 
growth. Exp Hematol. 2003;31:693–701.
  16.  Jayanthan A, Incoronato A, Singh A, et al. Cytotoxicity, drug combin-
ability, and biological correlates of ABT-737 against acute lymphoblastic 
leukemia cells with MLL rearrangements. Pediatr Blood Cancer. 
2011;56:353–360.
  17.  Battke F, Symons S, Nieselt K. Mayday – integrative analytics for 
expression data. BMC Bioinformatics. 2010;11:121–130.
  18.  Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns 
associated with recurrent chromosomal translocations in acute lym-
phoblastic leukemia. Blood. 2004;103:1043–1049.
  19.  Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations 
specify a distinct gene expression profile that distinguishes a unique 
leukemia. Nat Genet. 2002:30:41–47.
  20.  Yeoh E-J, Ross ME, Shurtleff SA, et al. Classification, subtype   discovery, 
and prediction of outcome in pediatric acute lymphoblastic leukemia 
by gene expression profiling. Cancer Cell. 2002;1:133–143.
 21.  Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblas-
tic leukemia by gene expression profiling. Blood. 2003;102:2951–2959.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
163
Identification of active agents for MLL-rearranged leukemia
  22.  Anderssen A, Eden P, Olofsson T, et al. Gene expression signatures 
in childhood acute leukemias are largely unique and distinct from 
those of normal tissues and other malignancies. BMC Med Genomics. 
2010;3:6–14.
  23.  Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of 
pediatric acute myelogenous leukemia. Blood. 2004;104:3679–3687.
  24.  Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value 
of the in vitro cell line, human xenograft, and mouse allograft preclinical 
cancer models. Clin Cancer Res. 2003;9:4227–4239.
  25.  Sigal DS, Miller HJ, Schram ED, Saven A. Beyond hairy cell: the 
activity of cladribine in other hematologic malignancies. Blood. 
2010;116:2884–2896.
  26.  Santana VM, Hurwitz Ca, Blakely RL et al. Complete hematologic 
remissions induced by 2-chlorodeoxyadenosine in children with newly 
diagnosed acute myeloid leukemia. Blood. 1994;84:1237–1242.
  27.  Santana VM, Mirro J Jr, Keams C, Schell MJ, Crom W, Blakley RL. 
2-chlorodeoxyadenosine produces a high rate of complete hemato-
logic remission in relapsed acute myeloid leukemia. J Clin Oncol. 
1992;10:364–370.
  28.  Gandhi V , Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorode-
oxyadenosine and arabinosylcytosine in patients with acute myelog-
enous leukemia: pharmacokinetic, pharmacodynamic, and molecular 
interactions. Blood. 1996;87:256–264.
  29.  Crews KR, Wimmer PS, Hudson JQ, Howard SC, Ribeiro RC, Razzouk 
BI. Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergo-
ing hemofiltration and hemodialysis for acute renal failure. J Pediat 
Hematol Onc. 2002;24:677–680.
  30.  Kolb EA, Steinherz PG. A new multidrug induction protocol with topote-
can, vinorelbine, thiotepa, dexamethasone and gemcitabine for relapsed 
or refractory acute leukemia. Leukemia. 2003;17:1967–1972.
  31.  Hiwarkar P, Arkenau H-T, Treleaven J, Morgan G, Potter M, Ethell M. 
The feasibility of using topotecan, vinorelbine, thiotepa and gemcitabine 
(TVTG) in adult patients with relapsed/refractory acute lymphoblastic 
leukaemia/lymphoma. Leukemia. 2008;22:1627–1629.
  32.  Egerton N. Optimizing ixabepilone treatment schedules in patients 
with advanced or metastatic breast cancer. Cancer Chemoth Pharm. 
2010;66:1005–1012.
  33.  Jacobs S, Fox E, Krailo M, et al. Phase II trial of ixabepilone admin-
istered daily for five days in children and young adults with refractory 
solid tumors: a report from the Children’s Oncology Group. Clin Cancer 
Res. 2010;16:750–754.
  34.  Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, 
Reynolds CP. National Cancer Institute pediatric preclinical testing 
program: model description for in vitro cytotoxicity testing. Pediatr 
Blood Cancer. 2011;56:239–249.
  35.  Lamm DL, McGee WR, Hale K. Bladder cancer: current optimal 
intravesical treatment. Urol Nurs. 2005;25:323–332.
  36.  Andersen SM, Rosada C, Dagnaes-Hansen F, et al. Topical applica-
tion of valrubicin has a beneficial effect on developing skin tumors. 
Carcinogenesis. 2010;31:1483–1490.
  37.  Ravandi F, Issa J-P, Garcia-Manero G, et al. Superior outcome with 
hypomethylating therapy in patients with acute myeloid leukemia and 
high-risk myelodysplastic syndrome and chromosome 5 and 7 abnor-
malities. Cancer. 2009;115:5746–5751.
  38.  Bryan J, Jabbour E, Prescott H, Garcia-Manero G, Issa JP, Kantarjian H. 
Current and future management options for myelodysplastic syndromes. 
Drugs. 2010;70:1381–1394.
  39.  Parikh SA, Hagop K, Garcia-Manero G, et al. Clofarabine plus low-dose 
cytarabine induction followed by consolidation with clofarabine plus 
low-dose cytarabine alternating with decitabine as frontline therapy 
for patients (pts) with acute myeloid leukemia (AML) = 60 years (yrs). 
Blood. 2009;114:Abstract No. 2058.
  40.  Ritchie EK, Arnason J, Feldman EJ, et al. Decitabine-based salvage ther-
apy in adults with acute myeloid leukemia. Blood. 2009;l114:Abstract 
No. 2063.
  41.  Dutcher JP, Coletti D, Paietta E, Wiernik PH. A pilot study of alpha-
interferon and plicamycin for accelerated phase of chronic myeloid 
leukemia. Leuk Res. 1997;21:375–342.
  42.  Archimbaud E, Troncy J, Sebban C, et al. Phase II trial of plicamycin 
and hydroxyurea in acute myelogenous leukemia. Cancer Chemoth 
Pharm. 1989;25:223–225.
  43.  Greil J, Gramatzki M, Burger R, et al. The acute lymphoblastic leukemia 
cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic 
and responsive to interleukin-7. Br J Haematol. 1994;86:275–283.
  44.  Cohen A, Brunberger T, Vanek W, et al. Constitutive expression and 
role in growth regulation of interleukin-1 and multiple cytokine recep-
tors in a biphenotypic leukemic cell line. Blood. 1991;78:94–102.
  45.  Matsuo Y, Drexler HG. Establishment and characterization of human 
B cell precursor-leukemia cell lines. Leuk Res. 1998;22:567–579.
  46.  Minowada J, Ohnuma T, Moore GE. Rosette-forming human lymphoid 
cell lines. I. Establishment and evidence for origin of thymus-derived 
lymphocytes. J Natl Cancer I. 1972;49:891–894.
  47.  Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. 
Establishment and characterization of a human acute monocytic leuke-
mia cell line (THP-1). Int J Cancer. 1980;26:171–176.
  48.  Adati N, Huang M-C, Suzuki T, Suzuki H, Kojima T. High-resolution 
analysis of aberrant regions in autosomal chromosomes in human 
leukemia THP-1 cell line. BMC Res Notes. 2009;2:153–159.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
164
Hoeksema et al
1.0E-02 1.0E-01
Concentration (µmol/L)
1.0E+00 1.0E+01
Celigo
Alamar blue
20
0
40
S
u
r
v
i
v
a
l
 
(
%
 
c
o
m
p
a
r
e
d
 
t
o
 
c
o
n
t
r
o
l
)
60
80
100
120
140
1.0E-02 1.0E-01
Concentration (µmol/L)
1.0E+00 1.0E+01
Sorafenib
Imatinib
20
0
40
S
u
r
v
i
v
a
l
 
(
%
 
c
o
m
p
a
r
e
d
 
t
o
 
c
o
n
t
r
o
l
)
60
80
100
120
140
A
C
1.0E-02 1.0E-01
Concentration (µmol/L)
1.0E+00 1.0E+01
20
0
40
S
u
r
v
i
v
a
l
 
(
%
 
c
o
m
p
a
r
e
d
 
t
o
 
c
o
n
t
r
o
l
)
60
80
100
120
140
1.0E-02 1.0E-01
Concentration (µmol/L)
1.0E+00 1.0E+01
Sunitinib
Gefitinib
20
0
40
S
u
r
v
i
v
a
l
 
(
%
 
c
o
m
p
a
r
e
d
 
t
o
 
c
o
n
t
r
o
l
)
60
80
100
120
140
B
D
Celigo
Alamar blue
Celigo
Alamar blue
Celigo
Alamar blue
Figure S1 comparison of cell survival measurements by the celigo™ cytometer and alamarBlue®. W1 leukemia cells were incubated with imatinib (A), gefitinib (B), 
sorafenib (C), or sunitinib (D) for 96 hours then measured using the celigo cytometer, followed by alamarBlue. survival compared with control DMsO-treated cells is shown, 
with data points and error bars representing the mean and standard error, respectively. 
Abbreviation: DMsO, dimethylsulfoxide.
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Table S1 ic50 values after incubation with drugs from the Approved Oncology Drug set ii
Drug name  
(NSC numbera)
IC50 (μmol/L)
Cell line
SEM B1 KOPN8 MOLT-3 TIB-202
Microtubule stabilizersb
Docetaxel  
(628503)
,1.00 × 10–2 2.78 × 10–4 ,1.00 × 10–2 ,1.00 × 10–2 5.88 × 10–2
Paclitaxel  
(125973)
,1.00 × 10–2 8.04 × 10–2 ± 3.49 × 10–2 ,1.00 × 10–2 1.00 × 101 1.06 × 10–1
Microtubule destabilizers
Vinblastine  
(49842)
1.00 × 10–2 9.93 × 10–4 ,1.00 × 10–2 8.51 × 10–1 8.79 × 10–3
Vincristine  
(67574)
,1.00 × 10–2 4.42 × 10–2 ,1.00 × 10–2 1.00 × 101 4.02 × 10–2
DNA damaging agents
Altretamine  
(13875)
.1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101
Bleomycin  
(125066)
,1.00 × 10–2 2.92 × 100 ± 2.23 × 100 1.08 × 10–1 8.42 × 100 1.07 × 100 ± 1.84 × 10–1
Busulfan  
(750)
.1.00 × 101 .1.00 × 101 .5.00 × 100 6.36 × 100 .5.00 × 100
carboplatin  
(241240)
.1.00 × 101 7.73 × 100 5.14 × 100 6.97 × 100 7.64 × 100
carmustine  
(409962)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
chlorambucil  
(3088)
7.29 × 100 6.41 × 100 3.38 × 100 5.56 × 100 4.47 × 100
cisplatin  
(119875)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
cyclophosphamide  
(26271)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
Dacarbazine  
(45388)
.1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101
estramustine  
(702294)
.1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101
ifosfamide  
(109724)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
Lomustine  
(79037)
9.35 × 100 8.32 × 100 .5.00 × 100 .1.00 × 101 .5.00 × 100
Melphalan  
(8806)
5.80 × 100 4.08 × 100 4.25 × 10–1 1.03 × 100 2.20 × 100
Mitomycin c  
(26980)
5.04 × 10–2 3.71 × 10–1 ± 5.56 × 10–2 5.94 × 10–2 ±  
4.38 × 10–2
2.21 × 10–2 8.55 × 10–2 ± 6.02 × 10–2
nitrogen mustard  
(762)
8.83 × 10–1 9.58 × 10–1 1.99 × 100 .1.00 × 101 3.42 × 100
Oxaliplatin  
(266046)
5.67 × 100 3.68 × 100 3.09 × 10–1 9.69 × 10–1 6.20 × 100
Pipobroman  
(25154)
4.32 × 100 2.63 × 100 3.89 × 10–1 6.35 × 100 4.34 × 100
Procarbazine  
(77213)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
streptozocin  
(85998)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
Temozolomide  
(362856)
9.12 × 100 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
Thiotepa  
(6396)
3.78 × 100 6.38 × 100 1.96 × 100 3.01 × 100 5.00 × 100
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Table S1 (Continued)
Drug name  
(NSC numbera)
IC50 (μmol/L)
Cell line
SEM B1 KOPN8 MOLT-3 TIB-202
Triethylenemelamine  
(9706)
4.81 × 10–1 3.97 × 10–1 1.97 × 10–1 2.60 × 10–1 4.47 × 10–1
Uracil mustard  
(34462)
4.85 × 100 3.65 × 100 2.22 × 100 9.66 × 100 2.70 × 100
DNA intercalating agents
Dactinomycin  
(3053)
,1.00 × 10–2 ,1.00 × 10–2 ,1.00 × 10–10 ,1.00 × 10–2 ,1.00 × 10–5
Daunorubicin  
(82151)
,1.00 × 10–2 9.45 × 10–3 ± 1.92 × 10–3 ,5.00 × 10–3 ,1.00 × 10–2 1.08 × 10–2
Doxorubicin  
(123127)
,1.00 × 10–2 1.20 × 10–1 ± 1.41 × 10–1 ,1.00 × 10–2 7.84 × 100 5.85 × 10–2
Mitoxantrone  
(279836)
,1.00 × 10–2 ,1.00 × 10–2 ,1.00 × 10–2 3.42 × 10–1 ,1.00 × 10–2
Nucleic acid synthesis inhibitors
capecitabine  
(712807)
.1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101
clofarabine  
(606869)
2.58 × 10–2 ,1.00 × 10–2 8.70 × 10–3 .1.00 × 101 ,1.00 × 10–2
Floxuridine  
(27640)
.1.00 × 101 8.48 × 100 .5.00 × 100 .1.00 × 101 .5.00 × 100
Fludarabine  
(312887)
8.87 × 10–2 9.09 × 10–2 7.05 × 10–2 .1.00 × 101 7.31 × 10–2
Fluorouracil  
(19893)
.1.00 × 101 .1.00 × 101 .5.00 × 100 7.11 × 100 .5.00 × 100
gemcitabine  
(613327)
,1.00 × 10–2 2.57 × 10–2 ± 1.03 × 10–2 ,5.00 × 10–3 ,1.00 × 10–2 5.65 × 10–2 ± 7.28 × 10–2
Hydroxyurea  
(32065)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
Mercaptopurine  
(755)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
nelarabine  
(686673)
.1.00 × 101 .1.00 × 101 .1.00 × 101 1.23 × 100 .1.00 × 101
Pemetrexed  
(698037)
.1.00 × 101 6.71 × 10–1 1.58 × 10–1 5.67 × 10–1 1.79 × 10–1
Pentostatin  
(218321)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
Thioguanine  
(752)
9.38 × 10–1 8.77 × 100 4.50 × 100 7.05 × 100 5.20 × 100
Aromatase inhibitors
Anastrozole  
(719344)
2.08 × 100 .1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101
exemestane  
(713563)
2.08 × 100 .1.00 × 101 8.89 × 100 .1.00 × 101 .1.00 × 101
Letrozole  
(719345)
.1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101
DNA methyltransferase inhibitors
Azacitidine  
(102816)
1.30 × 100 5.07 × 100 8.36 × 10–1 6.21 × 100 5.20 × 100
Histone deacetylase inhibitors
Vorinostat  
(701852)
.1.00 × 101 3.82 × 100 4.16 × 10–1 5.67 × 10–1 4.30 × 100
mTOR inhibitors
everolimus  
(733504)
,1.00 × 10–2 8.34 × 10–1 ,1.00 × 10–2 .1.00 × 101 ,1.00 × 10–2
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Table S1 (Continued)
Drug name  
(NSC numbera)
IC50 (μmol/L)
Cell line
SEM B1 KOPN8 MOLT-3 TIB-202
rapamycin  
(226080)
,1.00 × 10–2 8.04 × 10–3 ,1.00 × 10–2 ,1.00 × 10–2 7.05 × 100 ± 4.17 × 100
Proteasome inhibitors
Bortezomib  
(681239)
,1.00 × 10–2 3.97 × 10–3 ,1.00 × 10–2 .1.00 × 101 5.71 × 10–3
Tyrosine kinase inhibitors
Dasatinib  
(732517)
4.05 × 100 ,1.00 × 10–6 7.48 × 10–3 .1.00 × 101 ,1.00 × 10–6
imatinib  
(743414)
7.68 × 100 2.06 × 10–1 ± 1.34 × 10–2 .1.00 × 101 .1.00 × 101 2.70 × 10–1 ± 3.07 × 10–1
Lapatinib  
(745750)
4.73 × 100 5.70 × 100 5.20 × 100 .1.00 × 101 7.42 × 100
nilotinib  
(747599)
.1.00 × 101 ,1.00 × 10–2 .1.00 × 101 .1.00 × 101 ,1.00 × 10–2
sorafenib  
(747971)
1.54 × 100 5.66 × 100 3.86 × 100 9.63 × 100 5.95 × 100
sunitinib  
(750690)
1.35 × 10–1 5.36 × 100 3.30 × 100 .1.00 × 101 3.29 × 100
Topoisomerase poisons
etoposide  
(141540)
9.28 × 10–2 7.10 × 10–1 ± 5.81 × 10–1 1.97 × 10–2 1.07 × 10–1 4.56 × 10–1 ± 3.12 × 10–1
irinotecan  
(616348)
3.40 × 100 2.29 × 100 1.69 × 100 3.92 × 100 2.53 × 100
Teniposide  
(122819)
9.28 × 10–3 2.98 × 10–2 ± 3.09 × 10–2 1.80 × 10–4 1.17 × 10–2 4.91 × 10–2 ± 3.08 × 10–2
Topotecan  
(609699)
,1.00 × 10–2 2.76 × 10–2 ± 3.85 × 10–2 ,1.00 × 10–2 ,1.00 × 10–2 4.53 × 10–2
EGFR inhibitors
erlotinib  
(718781)
1.00 × 100 2.98 × 100 5.82 × 100 5.70 × 100 6.68 × 100
Gefitinib  
(715055)
4.89 × 100 5.16 × 100 5.08 × 100 .1.00 × 101 9.28 × 100
Estrogen receptor modulators
Fulvestrant  
(719276)
.1.00 × 101 .1.00 × 101 7.64 × 100 .1.00 × 101 .1.00 × 101
raloxifene  
(747974)
4.44 × 100 .1.00 × 101 8.30 × 100 .1.00 × 101 .1.00 × 101
Tamoxifen  
(180973)
.1.00 × 101 6.45 × 100 2.70 × 100 1.00 × 101 .5.00 × 100
Immunomodulatory agents
imiquimod  
(369100)
.1.00 × 101 .1.00 × 101 2.90 × 100 .1.00 × 101 .1.00 × 101
Lenalidomide  
(747972)
.1.00 × 101 .1.00 × 101 .1.00 × 101 1.00 × 101 .1.00 × 101
Thalidomide  
(66847)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
Photo-activated agents
Aminolevulinic acid  
(18509)
.1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101
Methoxsalen  
(45923)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
Protective adjuvant drugs
Allopurinol  
(1390)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
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Table S1 (Continued)
Drug name  
(NSC numbera)
IC50 (μmol/L)
Cell line
SEM B1 KOPN8 MOLT-3 TIB-202
Amifostine  
(296961)
.1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101
Dexrazoxone  
(169780)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
Zoledronic acid  
(721517)
.1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101
Miscellaneous drugs
Acrichine  
(14229)
6.40 × 100 4.63 × 100 7.22 × 10–1 4.07 × 100 4.50 × 100
Arsenic trioxide  
(92859)
.1.00 × 101 .1.00 × 101 1.69 × 10–1 .1.00 × 101 .1.00 × 101
celecoxib  
(719627)
.1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101 .1.00 × 101
Megestrol acetate  
(71423)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
Mitotane  
(38721)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
Tretinoin  
(122758)
.1.00 × 101 .1.00 × 101 .5.00 × 100 .1.00 × 101 .5.00 × 100
Notes: aCompound identification number in the National Cancer Institute/National Institutes of Health Developmental Therapeutics Program database; bsome drugs may 
have more than one mechanism of action.
Abbreviation: ic50, half maximal inhibitory concentration.